EF Hutton analyst Jason Kolbert lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $3 from $23 and keeps a Buy rating on the shares. Marinus announced that its Phase 3 TrustTSC trial evaluating oral ganaxolone for treating seizures associated with tuberous sclerosis complex did not meet the primary endpoint of reducing TSC-related seizure frequency, the analyst tells investors in a research note. The firm removed its estimates for the tuberous sclerosis complex but keeps a Buy rating given the stock’s “distressed valuation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNS:
- Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird
- Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities
- Marinus downgraded to Market Perform from Outperform at JMP Securities
- Marinus Pharmaceuticals downgraded to Hold from Buy at Truist
- Marinus notes TrustTSC trial misses primary endpoint, to evaluate alternatives
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
